MX2018006333A - Anticuerpos anti-receptor de muerte 5 (dr5) y metodos de uso de los mismos. - Google Patents

Anticuerpos anti-receptor de muerte 5 (dr5) y metodos de uso de los mismos.

Info

Publication number
MX2018006333A
MX2018006333A MX2018006333A MX2018006333A MX2018006333A MX 2018006333 A MX2018006333 A MX 2018006333A MX 2018006333 A MX2018006333 A MX 2018006333A MX 2018006333 A MX2018006333 A MX 2018006333A MX 2018006333 A MX2018006333 A MX 2018006333A
Authority
MX
Mexico
Prior art keywords
relates
molecules
antibody molecules
bind
antibodies
Prior art date
Application number
MX2018006333A
Other languages
English (en)
Spanish (es)
Inventor
Schuurman Janine
Parren Paul
Breij Esther
Rademaker Rik
Overdijk Marije
Strumane Kristin
Original Assignee
Genmab Bv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genmab Bv filed Critical Genmab Bv
Publication of MX2018006333A publication Critical patent/MX2018006333A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/526—CH3 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Cell Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
MX2018006333A 2015-12-01 2016-12-01 Anticuerpos anti-receptor de muerte 5 (dr5) y metodos de uso de los mismos. MX2018006333A (es)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
DKPA201500771 2015-12-01
DKPA201500787 2015-12-07
DKPA201500788 2015-12-07
DKPA201600702 2016-11-10
DKPA201600701 2016-11-10
PCT/EP2016/079518 WO2017093448A1 (en) 2015-12-01 2016-12-01 Anti-dr5 antibodies and methods of use thereof

Publications (1)

Publication Number Publication Date
MX2018006333A true MX2018006333A (es) 2018-08-01

Family

ID=58796495

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2018006333A MX2018006333A (es) 2015-12-01 2016-12-01 Anticuerpos anti-receptor de muerte 5 (dr5) y metodos de uso de los mismos.

Country Status (15)

Country Link
US (6) US20190144554A1 (enExample)
EP (4) EP3383905A1 (enExample)
JP (3) JP2019501151A (enExample)
KR (1) KR20180098567A (enExample)
CN (2) CN108884158A (enExample)
AU (2) AU2016363770A1 (enExample)
BR (2) BR112018011058A2 (enExample)
CA (1) CA3007031A1 (enExample)
IL (1) IL259713B2 (enExample)
MA (1) MA43365A (enExample)
MX (1) MX2018006333A (enExample)
SG (1) SG11201803956UA (enExample)
UA (1) UA126897C2 (enExample)
WO (2) WO2017093448A1 (enExample)
ZA (1) ZA201803079B (enExample)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2002362197A1 (en) * 2001-12-28 2003-07-24 Chugai Seiyaku Kabushiki Kaisha Method of stabilizing protein
UA117901C2 (uk) 2011-07-06 2018-10-25 Ґенмаб Б.В. Спосіб посилення ефекторної функції вихідного поліпептиду, його варіанти та їх застосування
MX2018006333A (es) 2015-12-01 2018-08-01 Genmab Bv Anticuerpos anti-receptor de muerte 5 (dr5) y metodos de uso de los mismos.
TWI808055B (zh) 2016-05-11 2023-07-11 美商滬亞生物國際有限公司 Hdac 抑制劑與 pd-1 抑制劑之組合治療
TWI794171B (zh) 2016-05-11 2023-03-01 美商滬亞生物國際有限公司 Ｈｄａｃ抑制劑與ｐｄ-ｌ１抑制劑之組合治療
CA3033665A1 (en) 2016-08-12 2018-02-15 Janssen Biotech, Inc. Fc engineered anti-tnfr superfamily member antibodies having enhanced agonistic activity and methods of using them
EP3635005A1 (en) * 2017-06-07 2020-04-15 Genmab B.V. Therapeutic antibodies based on mutated igg hexamers
KR20250020679A (ko) 2017-08-04 2025-02-11 젠맵 에이/에스 Pd-l1 및 cd137에 결합하는 결합제 및 그의 용도
MA50102A (fr) 2017-11-14 2020-07-15 Univ Virginia Patent Foundation Compositions et méthodes de fabrication et d'utilisation d'anticorps bispécifiques
CN109957020A (zh) * 2017-12-25 2019-07-02 深圳宾德生物技术有限公司 一种靶向dr5的单链抗体、嵌合抗原受体t细胞及其制备方法和应用
US12649798B2 (en) * 2018-01-24 2026-06-09 Genmab B.V. Polypeptide variants and uses thereof
MX2020011552A (es) 2018-05-03 2020-11-24 Genmab Bv Combinaciones de variantes de anticuerpos y usos de las mismas.
EP3820900A1 (en) * 2018-07-13 2021-05-19 Genmab A/S Variants of cd38 antibody and uses thereof
JP2022532812A (ja) * 2018-08-16 2022-07-20 カンタージア アクチエボラーグ 抗ｉｌ１ｒａｐ抗体組成物
US20220315661A1 (en) 2019-05-09 2022-10-06 Genmab B.V. Dosage regimens for a combination of anti-dr5 antibodies for use in treating cancer
GB201910900D0 (en) * 2019-07-31 2019-09-11 Scancell Ltd Modified fc-regions to enhance functional affinity of antibodies and antigen binding fragments thereof
JP7880817B2 (ja) 2019-11-06 2026-06-26 ジェンマブ ビー．ブイ． 抗体変種の組み合わせおよびその使用
MX2022014259A (es) * 2020-05-12 2022-12-07 Igm Biosciences Inc Uso de una molecula de union anti-dr5 multimerica en combinacion con una terapia contra el cancer para tratar el cancer.
CN111778333B (zh) * 2020-07-03 2022-11-18 东莞市滨海湾中心医院 测定edar表达水平的试剂的应用和试剂盒
US20230293680A1 (en) 2020-07-23 2023-09-21 Genmab B.V. A composition of anti-dr5 antibodies and an immunomodulatory imide drug for use in treating multiple myeloma
EP4214239A4 (en) * 2020-10-14 2025-07-09 Univ Virginia Patent Foundation COMPOSITIONS AND METHODS FOR OVERCOMING DR5-INDUCED IMMUNE EVASION BY SOLID TUMORS
CN112915211B (zh) * 2021-02-07 2022-05-06 成都中医药大学 一种pd-l1靶向肽药物偶联物及其合成方法和应用
WO2023023677A1 (en) * 2021-08-20 2023-02-23 University Of Virginia Patent Foundation Strategy for highly superior dr5 activation including in tumors and cancers
IL324457A (en) * 2023-05-12 2026-01-01 Genmab As Antibodies capable of binding to ox40, their variants and uses thereof
GB202315963D0 (en) * 2023-10-18 2023-11-29 Cancer Research Tech Ltd Binding molecules
WO2025160152A2 (en) * 2024-01-23 2025-07-31 The Regents Of The University Of California Fas antibody and its use in treating cancers

Family Cites Families (74)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US835A (en) 1838-07-12 X i i i x
US6077A (en) 1849-01-30 Improved hinged claw-wrench
US761218A (en) 1899-10-05 1904-05-31 U S Standard Voting Machine Co Register or counter.
US5703055A (en) 1989-03-21 1997-12-30 Wisconsin Alumni Research Foundation Generation of antibodies through lipid mediated DNA delivery
US6284236B1 (en) 1995-06-29 2001-09-04 Immunex Corporation Cytokine that induces apoptosis
KR970029803A (ko) 1995-11-03 1997-06-26 김광호 반도체 메모리장치의 프리차지 회로
CA2249206A1 (en) 1996-04-01 1997-10-09 Genentech, Inc. Apo-2li and apo-3 apoptosis polypeptides
ATE362982T1 (de) 1997-01-28 2007-06-15 Human Genome Sciences Inc ßDEATH-DOMAINß-ENTHALTENDER REZEPTOR 4 (DR4), EIN MITGLIED DER TNF-REZEPTOR SUPERFAMILIE, WELCHER AN TRAIL (APO-2L) BINDET
US6872568B1 (en) 1997-03-17 2005-03-29 Human Genome Sciences, Inc. Death domain containing receptor 5 antibodies
US20050233958A1 (en) 1997-03-17 2005-10-20 Human Genome Sciences, Inc. Death domain containing receptor 5
EP0979281B1 (en) 1997-05-02 2005-07-20 Genentech, Inc. A method for making multispecific antibodies having heteromultimeric and common components
CA2318029C (en) 1998-01-15 2009-05-19 Genentech, Inc. Apo-2 ligand
AU770718B2 (en) 1998-06-05 2004-02-26 Mayo Foundation For Medical Education And Research Use of genetically engineered antibodies to CD38 to treat multiple myeloma
US6355271B1 (en) 1999-02-03 2002-03-12 Biosante Pharmaceuticals, Inc. Therapeutic calcium phosphate particles and methods of manufacture and use
US6281005B1 (en) 1999-05-14 2001-08-28 Copernicus Therapeutics, Inc. Automated nucleic acid compaction device
ATE330972T1 (de) 1999-06-09 2006-07-15 Genentech Inc Apo-2l rezeptor-agonist und cpt-11 synergie- effekt
US6444640B1 (en) 1999-09-30 2002-09-03 Ludwig Institute For Cancer Research Compositions of trail and DNA damaging drugs and uses thereof
TWI318983B (en) 2000-05-02 2010-01-01 Uab Research Foundation An antibody selective for a tumor necrosis factor-related apoptosis-inducing ligand receptor and uses thereof
US7279160B2 (en) 2000-05-02 2007-10-09 The Uab Research Foundation Combinations of DR5 antibodies and other therapeutic agents
DE10043437A1 (de) 2000-09-04 2002-03-28 Horst Lindhofer Verwendung von trifunktionellen bispezifischen und trispezifischen Antikörpern zur Behandlung von malignem Aszites
US20020155109A1 (en) 2001-04-20 2002-10-24 Lynch David H. Bispecific antibodies that bind TRAIL-R1 and TRAIL-R2
KR100932577B1 (ko) 2001-05-18 2009-12-17 기린 홀딩스 가부시키가이샤 항 ｔｒａｉｌ-ｒ 항체
US7361341B2 (en) 2001-05-25 2008-04-22 Human Genome Sciences, Inc. Methods of treating cancer using antibodies that immunospecifically bind to trail receptors
MXPA03010747A (es) 2001-05-25 2004-03-02 Human Genome Sciences Inc Anticuerpos que se unen inmunoespecificamente a receptores de ligando inductor de apoptosis relacionado con factor de necrosis tumoral.
JP4509570B2 (ja) 2001-07-03 2010-07-21 ジェネンテック， インコーポレイテッド ヒトｄｒ４抗体及びその使用法
EP1506285B1 (en) 2001-11-01 2010-12-08 Uab Research Foundation Combinations of anti-dr5 antibodies and anti-dr4 antibodies and other therapeutic agents
US20040019915A1 (en) 2002-04-01 2004-01-29 Challita-Eid Pia M. Nucleic acid and corresponding protein entitled 213P1F11 useful in treatment and detection of cancer
KR100944575B1 (ko) 2002-10-17 2010-02-25 젠맵 에이/에스 Ｃｄ20에 대한 인간 모노클로날 항체
US20050266008A1 (en) 2004-03-29 2005-12-01 Medarex, Inc. Human anti-IRTA-5 antibodies
KR20070010046A (ko) 2004-04-06 2007-01-19 제넨테크, 인크. Ｄｒ5 항체 및 그의 용도
BRPI0514068B8 (pt) * 2004-08-04 2021-05-25 Applied Molecular Evolution Inc anticorpo anti-cd20, e, composição farmacêutica
US7741568B2 (en) 2005-01-13 2010-06-22 The Wiremold Company Downward facing receptacle assembly for cable raceway
CN101171034B (zh) 2005-03-03 2014-06-18 免疫医疗公司 人源化l243抗体
KR101374454B1 (ko) 2005-03-31 2014-03-17 추가이 세이야쿠 가부시키가이샤 회합제어에 의한 폴리펩티드 제조방법
PE20071101A1 (es) 2005-08-31 2007-12-21 Amgen Inc Polipeptidos y anticuerpos
EA015992B1 (ru) 2006-03-17 2012-01-30 Байоджен Айдек Эмэй Инк. Стабилизированное антитело и многовалентная антигенсвязывающая молекула на его основе, способы получения и использования вышеназванного стабилизированного антитела
DK1999154T3 (da) 2006-03-24 2012-12-03 Merck Patent Gmbh Fremstillede heterodimere proteindomæner
KR100847010B1 (ko) 2006-07-05 2008-07-17 아주대학교산학협력단 세포사멸 수용체 5 (ｄｒ5)에 특이적으로 결합하는 항체 및이를 포함하는 암 예방 또는 치료용 조성물
AT503902B1 (de) 2006-07-05 2008-06-15 F Star Biotech Forsch & Entw Verfahren zur manipulation von immunglobulinen
EP2158221B1 (en) 2007-06-21 2018-08-29 MacroGenics, Inc. Covalent diabodies and uses thereof
TW200904072A (en) 2007-07-05 2009-01-16 Ic Plus Corp System and method for generating interrupt
US20090162359A1 (en) 2007-12-21 2009-06-25 Christian Klein Bivalent, bispecific antibodies
US8242247B2 (en) 2007-12-21 2012-08-14 Hoffmann-La Roche Inc. Bivalent, bispecific antibodies
US9266967B2 (en) 2007-12-21 2016-02-23 Hoffmann-La Roche, Inc. Bivalent, bispecific antibodies
US8227577B2 (en) 2007-12-21 2012-07-24 Hoffman-La Roche Inc. Bivalent, bispecific antibodies
EP3663318A1 (en) 2008-01-07 2020-06-10 Amgen Inc. Method for making antibody fc-heterodimeric molecules using electrostatic steering effects
EP2310409A2 (en) 2008-06-17 2011-04-20 Apogenix GmbH Multimeric tnf receptors
EP2166021A1 (en) * 2008-09-16 2010-03-24 Ganymed Pharmaceuticals AG Monoclonal antibodies for treatment of cancer
JP5734201B2 (ja) 2008-12-19 2015-06-17 マクロジェニクス，インコーポレーテッド 共有結合型ダイアボディ及びその使用
US9067986B2 (en) 2009-04-27 2015-06-30 Oncomed Pharmaceuticals, Inc. Method for making heteromultimeric molecules
WO2010138725A1 (en) 2009-05-28 2010-12-02 Amgen Inc. Treatment of pancreatic cancer using a dr5 agonist in combination with gemcitabine
TWI507525B (zh) 2009-06-26 2015-11-11 Regeneron Pharma 具天然免疫球蛋白形式之易分離的雙專一性抗體
US9493578B2 (en) 2009-09-02 2016-11-15 Xencor, Inc. Compositions and methods for simultaneous bivalent and monovalent co-engagement of antigens
PT2560993T (pt) 2010-04-20 2024-09-16 Genmab As Proteínas contendo anticorpo heterodimérico fc e métodos para a produção das mesmas
WO2011143545A1 (en) 2010-05-14 2011-11-17 Rinat Neuroscience Corporation Heterodimeric proteins and methods for producing and purifying them
WO2012023053A2 (en) 2010-08-16 2012-02-23 Novimmune S.A. Methods for the generation of multispecific and multivalent antibodies
BR112013002167A2 (pt) 2010-08-24 2016-05-31 Roche Glycart Ag anticorpo biespecífico, composição farmacêutica, uso, método de tratamento de um paciente que sofre de câncer e de um paciente que sofre de inflamação
CN103068846B9 (zh) 2010-08-24 2016-09-28 弗·哈夫曼-拉罗切有限公司 包含二硫键稳定性Fv片段的双特异性抗体
CA2885176C (en) 2010-09-22 2018-10-23 Amgen Inc. Carrier immunoglobulins and uses thereof
BR112013010574A2 (pt) * 2010-10-29 2016-08-09 Daiichi Sankyo Co Ltd anticorpo, fragmento funcional do anticorpo, composição farmacêutica, usos de um anticorpo ou um fragmento funcional do mesmo e de pelo menos um membro selecionado do grupo que consiste de paclitaxel, carvoplatina, cpt-11, vinblastina, e 5-fu, polinucleotídeo, vetor, célula hospedeira transformada, e, método de produzir o anticorpo
CN103429620B (zh) 2010-11-05 2018-03-06 酵活有限公司 在Fc结构域中具有突变的稳定异源二聚的抗体设计
CN102250246A (zh) 2011-06-10 2011-11-23 常州亚当生物技术有限公司 抗VEGF/PDGFRβ双特异性抗体及其应用
UA117901C2 (uk) * 2011-07-06 2018-10-25 Ґенмаб Б.В. Спосіб посилення ефекторної функції вихідного поліпептиду, його варіанти та їх застосування
CN102654260B (zh) 2011-09-29 2014-09-03 北京京东方光电科技有限公司 一种背光源和液晶显示器
US9527927B2 (en) 2011-12-20 2016-12-27 Medimmune, Llc Modified polypeptides for bispecific antibody scaffolds
WO2013157953A1 (en) 2012-04-20 2013-10-24 Merus B.V. Methods and means for the production of ig-like molecules
WO2014006217A1 (en) * 2012-07-06 2014-01-09 Genmab B.V. Dimeric protein with triple mutations
DK2869845T3 (da) 2012-07-06 2019-12-09 Genmab Bv Dimert protein med tredobbelte mutationer
EP2684896A1 (en) * 2012-07-09 2014-01-15 International-Drug-Development-Biotech Anti-DR5 family antibodies, bispecific or multivalent anti-DR5 family antibodies and methods of use thereof
MX387324B (es) 2013-01-10 2025-03-18 Genmab Bv Variantes de regiones fc de igg1 de humano y usos de las mismas.
EP3048116A1 (en) * 2015-01-23 2016-07-27 International-Drug-Development-Biotech Anti-dr5 antibodies with enhanced apoptosis potency
MX2018006333A (es) 2015-12-01 2018-08-01 Genmab Bv Anticuerpos anti-receptor de muerte 5 (dr5) y metodos de uso de los mismos.
EP3535291A1 (en) 2016-11-01 2019-09-11 Genmab B.V. Polypeptide variants and uses thereof
BR112019015900A2 (pt) 2017-02-10 2020-04-07 Genmab B.V. polipeptídeo, métodos para aumentar a atividade agonística de um polipeptídeo, para aumentar a atividade de cdc de um polipeptídeo e de tratamento de um indivíduo tendo uma doença, composição, kit de partes, e, uso de um polipeptídeo ou uma composição

Also Published As

Publication number Publication date
WO2017093448A1 (en) 2017-06-08
EP4464333A3 (en) 2025-05-14
NZ743316A (en) 2023-12-22
EP4467648A3 (en) 2025-02-26
US20190144554A1 (en) 2019-05-16
AU2024200261A1 (en) 2024-02-01
JP7254515B2 (ja) 2023-04-10
EP4467648A2 (en) 2024-11-27
MA43365A (fr) 2018-10-10
ZA201803079B (en) 2023-12-20
US10882913B2 (en) 2021-01-05
CA3007033A1 (en) 2017-06-08
BR112018011100A2 (en) 2018-12-04
US20220411522A1 (en) 2022-12-29
JP2023022186A (ja) 2023-02-14
US20190315877A1 (en) 2019-10-17
IL259713B2 (en) 2026-03-01
JP7679347B2 (ja) 2025-05-19
WO2017093447A1 (en) 2017-06-08
EP3383905A1 (en) 2018-10-10
KR20180098567A (ko) 2018-09-04
EP3383906A1 (en) 2018-10-10
CN109476737A (zh) 2019-03-15
UA126897C2 (uk) 2023-02-22
US20190202926A1 (en) 2019-07-04
BR112018011058A2 (en) 2018-11-21
US20210324096A1 (en) 2021-10-21
JP2019501151A (ja) 2019-01-17
US20260176368A1 (en) 2026-06-25
JP2019500869A (ja) 2019-01-17
IL259713A (en) 2018-07-31
US12247080B2 (en) 2025-03-11
SG11201803956UA (en) 2018-06-28
AU2016363770A1 (en) 2018-06-28
IL259713B1 (en) 2025-11-01
CA3007031A1 (en) 2017-06-08
EP4464333A2 (en) 2024-11-20
CN108884158A (zh) 2018-11-23

Similar Documents

Publication Publication Date Title
ZA201803079B (en) Anti-dr5 antibodies and methods of use thereof
ZA202100721B (en) Anti-mesothelin antibodies
CR20200467A (es) Agentes anticuerpos anti-cd25
SA522431672B1 (ar) Cd3 أجسام مضادة للارتباط بـ
EA201792221A1 (ru) Антитела против сортилина и способы их применения
MX2024005027A (es) Anticuerpos de union a cd3.
EA201892294A1 (ru) Антитела и композиции против tim-3
MX393609B (es) Anticuerpos anti pd-1 y anti-lag3 para el tratamiento de cancer
EA201891178A1 (ru) Биспецифичные молекулы, обладающие иммунореактивностью в отношении pd-1 и ctla-4, и способы их применения
BR112017009264A2 (pt) proteína de ligação a epítopo ou um fragmento da mesma e imunoglobulina heterodimérica ou um fragmento da mesma
CR20160319A (es) Anticuerpo pd-1, fragmento de union al antigeno de este y uso médico de este
EA201890443A1 (ru) Биспецифичные моновалентные диатела, способные связывать b7-h3 и cd3, и их применение
AR109715A1 (es) Anticuerpos anti-cd27
PH12020552006A1 (en) Antibodies specific for cd3 and uses thereof
EA201790719A1 (ru) Биспецифические моновалентные диатела, которые способны связывать cd19 и cd3, а также их применения
JO3663B1 (ar) الأجسام المضادة لمضاد lag3 وأجزاء ربط الأنتيجين
JOP20160131B1 (ar) الأجسام المضادة للعامل xi وطرق الاستخدام
UY35042A (es) Anticuerpos anti-cd3, moléculas de unión a antígeno biespecíficas que se unen a cd3 y cd20, y usos de los mismos.
EA201690167A1 (ru) Гуманизованные или химерные антитела к cd3
AR109683A1 (es) Anticuerpos contra el factor xi y sus usos
EA202090791A1 (ru) Агонистические антитела против cd40
MX2020008122A (es) Anticuerpos anti-pd-1.
ZA202008095B (en) Humanized antibodies against psma
MX2020006155A (es) Moleculas de union a cd-16 biespecificas y su uso en el tratamiento de enfermedades.
PH12019500802A1 (en) Antibodies that bind zika virus envelope protein and uses thereof